Dr. Nicholas Galakatos is the Global Head of Life Sciences at Blackstone, and the Chairman of its Investment Committee. He joined Blackstone as part of its acquisition of Clarus in 2018. Dr. Galakatos was a co-Founder and Managing Director of Clarus since the firm's inception in 2005. He has over 30 years of industry and investment experience in the healthcare sector and has led investments in biotechnology, pharmaceutical company partnerships, and diagnostics, from startups to commercial-stage companies. Prior to Clarus he was Vice President of New Business at Millennium Pharmaceuticals (presently Takeda). Prior to that he led Molecular Biology Research at Ciba (presently Novartis). He was a founder of Millennium Predictive Medicine and TransForm Pharmaceuticals, where he was the Chairman and founding CEO. He has been a Director of over 20 public and private companies, and is currently the Chairman of Anthos Therapeutics, and a member of the Board of Directors of Neurvati and BioMed Realty. Also, he is a member of the Board of Trustees at Reed College.
Dr. Galakatos earned his PhD in Organic Chemistry from MIT and performed his post-doctoral studies at Harvard Medical School. He earned his undergraduate degree at Reed College.